Enterprise Value
376.3M
Cash
126M
Avg Qtr Burn
-21.48M
Short % of Float
3.93%
Insider Ownership
23.34%
Institutional Own.
43.92%
Qtr Updated
12/31/23
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
VTP-300 + Low dose nivolumab Details Hepatitis B | Phase 2b Data readout | |
AB-729 (GalNAc-RNAi) +VTP-300+nivolumab Details Hepatitis B | Phase 2a Data readout | |
Phase 2a Data readout | ||
AB-729 (GalNAc-RNAi) +NA therapy +IFN Details Hepatitis B | Phase 2a Data readout | |
AB-101 Details Hepatitis B | Phase 1 Data readout | |
AB-729-001 Details Hepatitis B | Phase 1a Update | |
AB-836 (capsid inhibitor) Details Hepatitis B | Failed Discontinued | |
AB-161 (Oral RNA destabilizer) Details Hepatitis B | Failed Discontinued |